Distinguishing Burkitt Lymphoma/Leukemia from Pre‑B Acute Lymphoblastic Leukemia

Diagnostic Overview

• Burkitt lymphoma/leukemia can be mistaken for pre‑B ALL, especially when Burkitt shows atypical immunophenotype or when pre‑B ALL harbors IG‑MYC rearrangements; this confusion has critical therapeutic consequences. (National Comprehensive Cancer Network – NCCN) 1, 2

Immunophenotypic Markers

Key Differentiating Antigens

• TdT status – Burkitt is TdT‑negative (the single most important distinguishing feature), whereas pre‑B ALL is uniformly TdT‑positive. (NCCN) 1, 3
• CD20 intensity – Burkitt exhibits bright CD20 expression in 86‑100 % of cases; pre‑B ALL shows dim or variable CD20 in only 30‑50 % of cases. (NCCN) 4
• Surface immunoglobulin – Positive with light‑chain restriction in Burkitt; negative in pre‑B ALL. (NCCN) 2
• CD10 – Positive in both entities, but remains a supportive rather than discriminating marker. (NCCN) 1, 2
• Ki‑67 proliferation index – Approaches 100 % in Burkitt, markedly lower in pre‑B ALL. (NCCN) 2
• BCL2 / BCL6 – Burkitt is BCL2‑negative and BCL6‑positive; BCL2 may be positive in pre‑B ALL. (NCCN) 2

Recommended Flow‑Cytometry Approach

• Perform comprehensive multicolor flow cytometry (≥ 8‑color panel) together with cytogenetic studies for reliable differentiation. (NCCN) 1, 3

Cytogenetic and Molecular Testing

• Burkitt‑defining lesions – Detect t(8;14) or other MYC rearrangements (e.g., t(2;8), t(8;22)) by FISH or conventional cytogenetics; presence confirms Burkitt. (NCCN) 2
• ALL‑defining lesions – Screen for common B‑ALL translocations: t(12;21)[ETV6::RUNX1], t(1;19)[TCF3::PBX1], t(9;22)[BCR::ABL1]. (NCCN) 5, 6
• IG‑MYC in TdT‑positive disease – When an IG‑MYC rearrangement is identified in a TdT‑positive case, classify as high‑risk B‑cell precursor ALL rather than Burkitt. (NCCN) 5

Treatment Implications

• Burkitt lymphoma/leukemia – Requires short‑duration, high‑intensity chemotherapy (e.g., CODOX‑M, hyper‑CVAD, dose‑adjusted EPOCH) plus rituximab; complete remission rates 75‑90 %. (NCCN) 2, 4
• Pre‑B ALL – Treated with prolonged ALL‑directed regimens that include induction, consolidation, and maintenance phases. (NCCN) 1, 5
• BCP‑ALL with IG‑MYC – Managed with intensive ALL therapy guided by minimal residual disease; Burkitt‑type regimens are not indicated unless poor response necessitates lymphoma‑directed treatment. (NCCN) 5

Clinical Pitfalls and Additional Considerations

• Morphology alone is insufficient – FAB L3 morphology with vacuolization can appear in both entities; always corroborate with immunophenotype and cytogenetics. (NCCN) 1, 2
• TdT‑negative disease is not exclusive to Burkitt – Rare TdT‑negative AML cases exist; additional myeloid markers are required for exclusion. (NCCN) 1
• WHO 2008 classification – Recognizes that distinguishing DLBCL from Burkitt may be impossible on immunophenotype alone; aggressive therapy is justified when a definitive distinction cannot be made. (World Health Organization) 2
• Bone‑marrow involvement threshold – When > 25 % blasts are present in marrow, the disease is classified as leukemia rather than isolated lymphoma. (NCCN) 5

Strength of evidence: Specific levels of evidence were not detailed in the source articles; recommendations are based on consensus guidelines and expert opinion.